A 15-day course of donepezil modulates spectral EEG dynamics related to target auditory stimuli in young, healthy adult volunteers. Issue 5 (May 2019)

• Record Type: Journal Article
• Authors: Leroy, Christopher; Bourriez, Jean-Louis; Dujardin, Kathy; Molaee-Ardekani, Behnam; Babiloni, Claudio; Deplanque, Dominique; Ponchel, Amélie; Hennion, Sophie; Plomhause, Lucie; Devanne, Hervé; Deguil, Julie; Payoux, Pierre; Blin, Olivier; Méligne, Déborah; Micallef, Joëlle; Chauveau, Nicolas; Lanteaume, Laura; Vervueren, Céline; Guimont, François; Thalamas, Claire; Cassé-Perrot, Catherine; Rouby, Franck; Bordet, Régis; Derambure, Philippe
• Is Part Of: Clinical neurophysiology. Volume 130:Issue 5(2019:May)
• Page Start: 863
• Page End: 875
• Publication Date: 2019-05
• Subjects: AD Alzheimer's disease -- EEG electroencephalographic -- AChEI acetylcholinesterase inhibitor -- ERP event-related potential -- ITC inter-trial coherence -- ERSP event-related spectral perturbation -- CSD current source density -- ERS event-related-synchronization -- ERD event-related-desynchronization -- PCA principal component analysis; Donepezil -- EEG markers -- Event-related potential -- Inter-trial coherence -- Event-related spectral perturbation; Neurophysiology -- Periodicals; Electroencephalography -- Periodicals; Electromyography -- Periodicals; Neurology -- Periodicals; 612.8
• DOI: 10.1016/j.clinph.2015.11.018
• Languages: English
• ISSNs: 1388-2457

Abstract

Highlights: Time–frequency analyses were used to identify dynamic electroencephalographic markers of donepezil's effect in healthy young adults. Inter-trial coherence and event-related spectral perturbation analyses can detect subtle changes related to donepezil's effects. Electroencephalography may be a valuable tool for predicting the efficacy of drug candidates prior to Phase II/III clinical trials in Alzheimer's disease. Abstract: Objective: To identify possible electroencephalographic (EEG) markers of donepezil's effect on cortical activity in young, healthy adult volunteers at the group level. Methods: Thirty subjects were administered a daily dose of either 5 mg donepezil or placebo for 15 days in a double-blind, randomized, cross-over trial. The electroencephalogram during an auditory oddball paradigm was recorded from 58 scalp electrodes. Current source density (CSD) transformations were applied to EEG epochs. The event-related potential (ERP), inter-trial coherence (ITC: the phase consistency of the EEG spectrum) and event-related spectral perturbation (ERSP: the EEG power spectrum relative to the baseline) were calculated for the target (oddball) stimuli. Results: The donepezil and placebo conditions differed in terms of the changes in delta/theta/alpha/beta ITC and ERSP in various regions of the scalp (especially the frontal electrodes) but not in terms of latency and amplitude of the P300-ERP component. Conclusion: Our results suggest that ITC and ERSP analyses can provide EEG markers of donepezil's effects in young, healthy, adult volunteers at a group level. Significance: Novel EEG markers could be useful to assess the therapeutic potential of drug candidates in Alzheimer's disease in healthy volunteers prior to the initiation of Phase II/III clinical studies in patients.